骨质疏松症与更年期的关系:文献综述

H. Alsarraje, *Liqaa Khalel Alhyali
{"title":"骨质疏松症与更年期的关系:文献综述","authors":"H. Alsarraje, *Liqaa Khalel Alhyali","doi":"10.37648/ijrmst.v14i01.016","DOIUrl":null,"url":null,"abstract":"Osteoporosis is the most problem of women's bone disease, it has a multitude of causes, including menopause. It affects about one in three women. Before a fracture, osteoporosis does not exhibit any clinical symptoms. Important pathology is brought on by fractures. Postmenopausal osteoporosis can be avoided with early diagnosis of this condition before fractures happen; Menopausal hormone therapy (MHT) significantly reduces the fracture risk in all body bones by halting bone loss and degeneration of bone microstructure. The fast bone loss brought on by declining estrogen peaks in the first two to three years following menopause. Even in women with modest fracture risk, MHT is the only antiosteoporosis medication that has been shown to be effective regardless of baseline risk . There is no rationale for using specific, efficient drugs to treat osteoporosis, making MHT the first option for maintaining bone health in women. It is also advisable to evaluate the advantages and risks of MHT. MHT has become the leading therapeutic choice for preserving bone health in early postmenopausal women.","PeriodicalId":178707,"journal":{"name":"International Journal of Research in Medical Sciences and Technology","volume":"130 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Relationship of Osteoporosis with Menopause: Review of Article\",\"authors\":\"H. Alsarraje, *Liqaa Khalel Alhyali\",\"doi\":\"10.37648/ijrmst.v14i01.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Osteoporosis is the most problem of women's bone disease, it has a multitude of causes, including menopause. It affects about one in three women. Before a fracture, osteoporosis does not exhibit any clinical symptoms. Important pathology is brought on by fractures. Postmenopausal osteoporosis can be avoided with early diagnosis of this condition before fractures happen; Menopausal hormone therapy (MHT) significantly reduces the fracture risk in all body bones by halting bone loss and degeneration of bone microstructure. The fast bone loss brought on by declining estrogen peaks in the first two to three years following menopause. Even in women with modest fracture risk, MHT is the only antiosteoporosis medication that has been shown to be effective regardless of baseline risk . There is no rationale for using specific, efficient drugs to treat osteoporosis, making MHT the first option for maintaining bone health in women. It is also advisable to evaluate the advantages and risks of MHT. MHT has become the leading therapeutic choice for preserving bone health in early postmenopausal women.\",\"PeriodicalId\":178707,\"journal\":{\"name\":\"International Journal of Research in Medical Sciences and Technology\",\"volume\":\"130 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Research in Medical Sciences and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37648/ijrmst.v14i01.016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Research in Medical Sciences and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37648/ijrmst.v14i01.016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

骨质疏松症是女性骨骼疾病中最严重的问题,它有多种原因,包括更年期。大约三分之一的女性受到影响。骨折前,骨质疏松症不表现出任何临床症状。重要的病理是由骨折引起的。绝经后骨质疏松症可以通过在骨折发生前早期诊断来避免;绝经期激素治疗(MHT)通过阻止骨质流失和骨骼微结构退化,显著降低所有身体骨骼的骨折风险。在绝经后的前两到三年,由于雌激素下降而导致的骨质快速流失达到顶峰。即使在有中度骨折风险的女性中,MHT也是唯一被证明有效的抗骨质疏松药物,无论基线风险如何。没有理由使用特定的、有效的药物来治疗骨质疏松症,这使得MHT成为维持女性骨骼健康的第一选择。评估MHT的优势和风险也是可取的。MHT已成为保留早期绝经后妇女骨骼健康的主要治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Relationship of Osteoporosis with Menopause: Review of Article
Osteoporosis is the most problem of women's bone disease, it has a multitude of causes, including menopause. It affects about one in three women. Before a fracture, osteoporosis does not exhibit any clinical symptoms. Important pathology is brought on by fractures. Postmenopausal osteoporosis can be avoided with early diagnosis of this condition before fractures happen; Menopausal hormone therapy (MHT) significantly reduces the fracture risk in all body bones by halting bone loss and degeneration of bone microstructure. The fast bone loss brought on by declining estrogen peaks in the first two to three years following menopause. Even in women with modest fracture risk, MHT is the only antiosteoporosis medication that has been shown to be effective regardless of baseline risk . There is no rationale for using specific, efficient drugs to treat osteoporosis, making MHT the first option for maintaining bone health in women. It is also advisable to evaluate the advantages and risks of MHT. MHT has become the leading therapeutic choice for preserving bone health in early postmenopausal women.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信